On a disclosed basis, annual sales rose from KRW 59.1 billion in 2022 to KRW 71.3 billion in 2023 (up 20.7% year on year) and KRW 87.6 billion in 2024 (up 22.8%), then fell to KRW 59.3 billion in 2025 (down 32.3%). 2024 was the largest year in the 2022–2025 period and 2022 the smallest.
Operating performance moved from an operating loss of KRW 18.5 billion in 2022 to an operating profit of KRW 2.59 billion in 2023, a swing to profit, and rose to KRW 2.85 billion in 2024 (up 10.4%). In 2025 the company swung back to an operating loss of KRW 19.2 billion.
Operating margins were -31.4% in 2022, 3.6% in 2023, 3.3% in 2024, and -32.3% in 2025. In 2023 and 2024 sales growth coincided with a positive operating margin, while in 2025 the sales decline came with a sharp margin reversal.
The net loss attributable to controlling shareholders was KRW 38.5 billion in 2022, narrowed to KRW 3.36 billion in 2023, widened to KRW 9.98 billion in 2024, and reached KRW 32.4 billion in 2025.
The net loss including non-controlling interests was KRW 39.2 billion in 2022, KRW 3.36 billion in 2023, KRW 9.98 billion in 2024, and KRW 32.4 billion in 2025, and the company has reported losses in each of the four years from 2022 to 2025.
The debt ratio, defined as total liabilities divided by total equity, was 76.8% in 2022, 66.9% in 2023, 73.3% in 2024, and 127.7% in 2025. Operating cash flow went from -KRW 3.32 billion in 2022 to KRW 2.99 billion in 2023 and KRW 5.73 billion in 2024, then turned to -KRW 6.87 billion in 2025.
On a quarterly basis, sales rose from KRW 6.76 billion in Q3 2025 with an operating loss of KRW 10.2 billion to KRW 16.2 billion in Q4 2025 (up 139.7% quarter on quarter), and the operating loss narrowed to KRW 3.73 billion.
Sales then declined to KRW 14.1 billion in Q1 2026 (down 12.9%) and KRW 13.3 billion in Q2 2026 (down 5.8%), while operating losses narrowed to KRW 3.02 billion and KRW 1.94 billion. Q3 2026 sales were KRW 15.6 billion (up 17.8% quarter on quarter and up 131.5% year on year), and the operating loss was KRW 281 million.
The net loss attributable to controlling shareholders narrowed from KRW 11.6 billion in Q3 2025 and KRW 12.8 billion in Q4 2025 to KRW 806 million in Q3 2026, and the four quarters from Q4 2025 to Q3 2026 total KRW 22 billion.
The company has posted an operating loss and a net loss attributable to controlling shareholders for five consecutive quarters from Q3 2025 to Q3 2026.
The quarterly sales recovery overlaps with the timing of the Anaprazole launch, and the sales breakdown by quarter comes from the segment information in the periodic reports.